Global Equity Strategy: Opportunities In Real Estate and Health Care
The weight of the evidence continues to support our mixed, but overall constructive outlook. We outline the basis for our outlook and also...
179 Views
SK Bioscience IPO - Valuation Analysis
We believe that SK Bioscience's market cap value could be about 11.5 trillion won or 149,000 won per share which would represent 129% higher than...
337 Views
SK Bioscience IPO Preview - Biggest IPO in Korea in 1Q 2021
SK Bioscience is getting ready to complete its IPO in Korea in March. SK Bioscience will be the biggest IPO in Korea so far this year in 2021. The...
426 Views
Lonza: A Bellwether Biopharma Focused CDMO | At Inflection Point, To Benefit from Ongoing Capex
Over the next few weeks/months, we will be initiating coverage on a few key players in the Global CDMO space, where we see interesting growth...
450 Views
Global Equity Strategy: Buy the Dips
Despite recent weakness across global markets, our weight of the evidence approach continues to lead us to the same conclusions as we posited in...
423 Views